Here is the question investors should sit with before Monday: Eli Lilly is now generating enough cash from weight-loss drugs to build an entirely new therapeutic franchise. Is anyone pricing that in?
Bloomberg reported September 10, 2026 that Lilly has been laying the groundwork for a broader move into women’s health, assembling experts and hunting for new medicines across conditions including bone health and endometriosis. The move shows the unconventional steps the world’s largest pharmaceutical company is taking with the windfall from its weight-loss and diabetes shots to find its next act. The report landed four days before Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities, takes part in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 1:50 p.m. Eastern time. Yuffa is the executive who oversees both U.S. commercial execution and global customer strategy, making him the right person to field questions about how far Lilly’s ambitions actually extend.
The Machine Behind the Bet
Lilly reported second-quarter revenue of $23.0 billion, a 48% increase from a year earlier, and lifted its full-year revenue target to a range of $85 billion to $87 billion. Mounjaro revenue rose 91% to $9.9 billion for the quarter. That global Mounjaro number is the one that matters most for the next chapter: it confirms a global demand base that Lilly is now trying to serve with a pill, not just a shot.
On April 1, 2026, the FDA approved Foundayo, Lilly’s oral GLP-1 pill for chronic weight management, and Lilly said the drug can be taken any time of day without food or water restrictions. While Novo Nordisk leverages its first-mover advantage with the familiar Wegovy brand, Lilly is betting that the freedom from strict fasting and water requirements can give Foundayo an edge. The early U.S. demand has looked strong, but weekly prescription figures vary by data source and tracking method.
The International Clock Is Running
Foundayo is currently under regulatory review in more than 40 additional countries, and Lilly expects to launch in most international markets by 2027. The geographic footprint is already expanding: Lilly has launched Foundayo for obesity in the UAE, and regulators in Saudi Arabia and Mexico have approved it. In Europe, the UK’s Medicines and Healthcare products Regulatory Agency has approved Foundayo, intensifying competition further between Lilly and Novo Nordisk. Reuters has reported that Lilly plans to launch Foundayo in Europe by the end of 2026 or early 2027, focusing on the direct-to-consumer market, and will team up with telehealth companies as it has in the United States.
Bull Case and Bear Case
The bull case rests on compounding. A $23 billion quarterly revenue run rate gives Lilly the capital to fund women’s health research, absorb the cost of a 40-country regulatory campaign, and still invest in manufacturing. Management announced a $4.5 billion capital spend across Indiana manufacturing sites that it said would support planned production of Foundayo and retatrutide. That is not the behavior of a company worried about sustaining the obesity windfall.
The bear case is execution risk at scale. Competitive pressures are emerging globally as payers and regulators push back on pricing, and as rival incretin products advance. The women’s health build-out is early and unproven. And Lilly has also flagged that comparisons later in 2026 get harder because earlier periods benefited from items such as adjustments for rebates and discounts.
What to Watch Monday
Yuffa’s comments should answer two specific questions: how quickly international Foundayo approvals convert to commercial launches, and whether the women’s health initiative has a dedicated capital commitment or remains exploratory. If he signals a defined budget for women’s health alongside a tightened timeline for the global Foundayo rollout, the market will have something concrete to price in. If the language stays vague, investors are left extrapolating from Bloomberg’s sourcing.
Lilly is no longer a one-drug story. Whether the women’s health franchise becomes a second pillar or remains an aspiration is exactly what Monday’s session is built to clarify.
